A higher tissue concentration can hide a delivery problem. An antibody may accumulate around tumor vessels while leaving more distant cells underexposed, or remain associated with brain endothelium without reaching the cells its cargo needs to enter. Either result can look encouraging in an uptake assay while leaving the central pharmacological question unanswered.

For biologic drug design, penetration and retention have to be judged together: how much active material reaches the relevant compartment, how long it remains available, and what it does there. That puts size, binding kinetics, receptor choice, and trafficking into the same design conversation. Improving one property is useful only if the complete molecule delivers more of the activity the program needs.

Tumor uptake can leave important gaps

Within a solid tumor, extravasation, interstitial movement, binding, and internalization compete on different timescales. A molecule that binds rapidly after leaving a vessel may be captured before it moves much farther. High antigen density and slow dissociation can strengthen that local sink, while internalization continually removes bound material from the extracellular pool. Substantial tumor uptake can therefore coexist with poor spatial coverage.

An affinity series becomes much more informative when teams can see where each variant goes. How far does it distribute from vessels? Which regions remain underexposed? Does increasing the dose improve coverage, or mainly increase accumulation near the vasculature? Those comparisons reveal whether an engineering change has relieved a binding-site barrier. Bulk tumor concentration cannot answer that on its own.

Equilibrium affinity also leaves out part of the story. Variants with similar dissociation constants can have different association and dissociation kinetics, and multivalent rebinding changes effective residence time again. The useful comparison connects those measurements with cell-surface behavior and distribution in the intended therapeutic format. Otherwise, a favorable binding result can steer the team toward an architecture that reinforces the delivery problem.

Smaller formats need enough time to work

Compact scaffolds offer a practical route to broader tissue distribution. Their potential is especially attractive for conjugates, where reaching additional tumor cells can extend payload delivery beyond the regions served by a larger construct. But faster diffusion has to be considered alongside the duration of the circulating supply.

A rapidly cleared molecule may reach distant cells efficiently during a short exposure window and still fail to sustain the occupancy another mechanism requires. Adding a half-life extension element may improve supply, but it also changes the construct being optimized. The distribution advantage needs to be checked again in that new format.

For a conjugate program, the comparison should connect circulating intact conjugate, spatial tumor distribution, internalization, and payload activity. Where formats differ substantially in clearance, exposure needs to be considered before an efficacy difference is attributed to penetration. A scaffold that reaches more cells and one that delivers more total material may both improve activity, but they point to different next steps in engineering and dosing.

Brain retention only helps in the right compartment

Brain delivery makes the distinction between accumulation and useful exposure particularly clear. Material retained at the vasculature contributes to a whole-brain measurement, yet may offer little value to a cargo that needs to act inside neurons. Receptor choice therefore needs to account for the route the construct takes after binding, as well as how much enters or remains associated with the tissue.

Transferrin receptor and CD98-directed shuttles illustrate the competing possibilities. Depending on the construct and experimental system, transferrin receptor engagement can favor rapid uptake and subsequent entry into neurons and other brain cells, followed by intracellular degradation. CD98 engagement can favor longer retention with a greater vascular association. Neither profile establishes the preferred design without knowing where the cargo needs to act.

Dual-receptor formats offer another way to adjust that balance. Changing relative receptor affinities can shift uptake kinetics, peak concentrations, retention, and cellular localization. The opportunity is to tune delivery toward the required pharmacology, with the recognition that stronger retention may come with less neuronal internalization.

These constructs need time-resolved comparisons with their single-receptor controls, including localization and cargo activity. Higher whole-brain exposure is encouraging when the additional material reaches the cells and compartment responsible for the effect. Without that connection, the measurement leaves the most consequential delivery question open.

Select for the trafficking behavior the cargo needs

Rapid internalization is valuable only when the subsequent route supports the modality. Receptor downregulation, antibody-drug conjugate payload delivery, and nucleic acid delivery have different intracellular requirements. An antibody can perform well in an uptake screen and still send its cargo somewhere unproductive.

Discovery workflows can address this earlier by selecting for functional transport behavior. Linking antibody-mediated uptake to a downstream delivery readout gives teams a way to enrich candidates for more than binding or disappearance from the cell surface. That approach is particularly useful when receptor fate is part of the intended mechanism.

Candidate ranking should connect uptake, trafficking, and the cargo’s functional response, then be revisited after conjugation or format conversion. An internalization advantage that disappears in the final architecture should affect the development decision. Testing isolated binding domains may clarify individual properties, but the complete molecule has to demonstrate that those properties work together.

Set residence time against the required effect

Longer retention carries different value across modalities. Sustained extracellular blockade may require continued access to the target, while a payload-delivery strategy may achieve useful activity through efficient entry during a shorter exposure window. Radioimmunotherapy adds the duration of normal-tissue exposure to the same calculation.

For radiolabeled formats, faster clearance can be desirable if it reduces normal-tissue radiation exposure while preserving sufficient tumor targeting and retention. That objective can support an intermediate-sized fragment even when extending systemic half-life would be attractive for another program. Tumor residence and clearance elsewhere need to be evaluated jointly.

The same discipline applies to every proposed engineering change. Lower affinity should improve spatial coverage while preserving adequate engagement. Half-life extension should increase useful exposure enough to justify any change in distribution. A new shuttle receptor should improve delivery to the relevant cells, and stronger retention should prolong measurable activity where it is needed.

Putting those expectations into candidate comparisons makes the tradeoffs easier to interpret. It also gives teams a clearer basis for deciding when further optimization is worthwhile and when a different format or targeting strategy deserves consideration.

Make productive exposure the design objective

The most useful delivery data connect location, time, and function. Spatial measurements explain who is being reached, trafficking studies show where the molecule goes next, and functional readouts establish whether that exposure is doing the intended work. Together, they reveal limitations that a higher tissue concentration can obscure.

This is where penetration and retention become actionable design choices. The goal is enough active material in the right compartment for long enough to produce the required effect, within an acceptable exposure profile elsewhere. Keeping that objective visible helps teams choose molecular changes that improve therapeutic performance rather than an isolated delivery metric.

Continue the conversation at PEGS AI

Carry the conversations from PEGS Europe into PEGS AI in January. Join the PEGS community to explore how AI can inform protein design and the experimental decisions that move promising molecules forward.

Register for PEGS AI